Pavel Raifeld to continue the implementation of the Company’s strategy and focus on value creation for shareholders
Innoviva, (“Innoviva”) today announced the appointment of Pavel Raifeld as Chief Executive Officer effective May 20, 2020. Mr. Raifeld is a seasoned healthcare executive with a strong background in strategy, business development and corporate finance and has focused much of his career on the creation of significant shareholder value. Mr. Raifeld replaces Geoff Hulme, who served as the Company’s principal executive officer since May 2018.
Read More: GlobalFintechSeries Interview with Brandon Dewitt, Co-founder and CTO at MX
Prior to joining Innoviva, Pavel Raifeld, CFA, served on the investment team at Sarissa Capital Management LP, an investment management firm focused on improving strategies of companies to enhance shareholder value. Earlier, he was a senior member of the healthcare investment banking team at Credit Suisse (USA) LLC. Previously, Mr. Raifeld worked as a consultant, primarily specializing in advising biopharmaceutical companies, at McKinsey & Company, Inc. and The Boston Consulting Group Ltd. Mr. Raifeld earned an AB degree from Harvard University and an MBA degree from Columbia University.
Read More: Strider Announces John Mullen, Former Assistant Director of CIA, Joins Company as Advisor
Dr. Odysseas Kostas, Chairman of the Board of Innoviva, stated, “We are excited to have Pavel join us. We believe the Company will benefit from his background and experience as the Company continues to move forward on the Board’s strategy to maximize shareholder value and its focus on capital allocation. On behalf of the Board and all Innoviva employees, I would also like to thank Geoff for his commitment and many contributions to the Company.”
Mr. Raifeld said, “I am honored by and excited about the opportunity to lead Innoviva. I look forward to working alongside the experienced Board and talented team to build an even brighter future for this great company.”
